LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand

LENZ Therapeutics entered an exclusive license and commercialization agreement with Arrotex Pharmaceuticals to distribute VIZZ in Australia and New Zealand. Terms include an upfront payment and a profit share on gross margin for LENZ, though specific financial figures were not disclosed. This marks LENZ's fifth ex-US partnership for VIZZ, an FDA-approved eye drop for presbyopia which has been commercially available in the U.S.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.